Active Smoking is a Relative Contraindication to Bronchoscopic Lung Volume Reduction
Patients who continue smoking are generally not candidates for bronchoscopic lung volume reduction (BLVR), though smoking is considered a relative rather than absolute contraindication. The evidence consistently demonstrates that active smoking represents a significant barrier to BLVR eligibility, accounting for approximately 16% of exclusions in real-world practice 1.
Evidence-Based Rationale
Smoking as a Contraindication
The most recent and comprehensive guideline on fitness for lung interventions emphasizes that smoking cessation should be included as a risk-modifying procedure in perioperative management 2. While this guideline addresses surgical lung volume reduction, the principles directly apply to bronchoscopic approaches given the similar physiologic demands and complication profiles.
In a real-world screening study of 138 patients referred for BLVR evaluation, 16% were excluded specifically due to active smoking 1. This represents the second most common reason for exclusion after emphysema morphology issues, highlighting the practical importance of smoking status in patient selection.
Why Smoking Matters for BLVR
The rationale for excluding active smokers includes:
- Increased complication risk: Smoking impairs wound healing and increases infection risk, which is particularly relevant given that BLVR can cause pneumothorax, pneumonia, and other pulmonary complications
- Ongoing lung damage: Continued smoking accelerates emphysema progression, potentially negating any benefits from volume reduction
- Poor treatment outcomes: The inflammatory effects of active smoking may compromise the intended physiologic improvements from BLVR
Smoking Cessation Recommendations
Multiple high-quality guidelines consistently recommend smoking cessation for COPD patients:
- Smoking cessation is strongly recommended (Grade 1C) for all patients with lung disease being considered for any intervention 3
- The 2020 lung cancer supportive care guideline states that smoking in itself is not a contraindication for receiving treatment, but patients should be actively supported to quit 4
- Smoking cessation improves outcomes even with shorter intervals before procedures 2
Clinical Algorithm for Decision-Making
Step 1: Assess Current Smoking Status
- Document pack-years and current smoking frequency
- Verify with biochemical testing (cotinine) if needed
Step 2: Determine Candidacy
- Active smoker (within 2-4 weeks): Not a candidate; initiate intensive smoking cessation program
- Recent quitter (quit 1-2 months ago): Borderline candidate; consider delaying BLVR to ensure sustained abstinence
- Former smoker (quit >2 months ago): Proceed with full BLVR evaluation
Step 3: Implement Smoking Cessation if Needed
- Provide intensive counseling (individual and group sessions)
- Prescribe pharmacologic support (nicotine replacement, varenicline, or bupropion)
- Arrange telephone follow-up contacts
- Document abstinence before proceeding with BLVR evaluation
Step 4: Re-evaluate After Cessation
- Confirm sustained abstinence for at least 2 months
- Reassess pulmonary function and other eligibility criteria
- Proceed with BLVR workup if all criteria met
Important Caveats
Do not delay evaluation indefinitely waiting for smoking cessation. While active smoking is a contraindication, the emphasis should be on concurrent smoking cessation intervention rather than automatic exclusion 4. Cancer diagnosis or severe COPD symptoms represent "teachable moments" for smoking cessation 4.
The duration of required abstinence is not firmly established. While some studies suggest 4-8 weeks of cessation reduces complications 5, 6, the evidence is not strong enough to mandate specific timeframes. Clinical judgment should prevail, weighing disease severity against smoking status.
Smoking cessation benefits extend beyond BLVR eligibility, including reduced exacerbation rates, improved survival, and decreased risk of second primary cancers 4, 7. Therefore, intensive cessation efforts are warranted regardless of whether the patient ultimately qualifies for BLVR.
Real-World Considerations
In clinical practice, only 27.5% of patients referred for BLVR ultimately receive the procedure 1. Active smoking represents a modifiable exclusion criterion, unlike anatomic factors or severe comorbidities. This underscores the importance of aggressive smoking cessation interventions in the pre-screening phase.
Patients should not be told they are permanently ineligible due to smoking. Instead, frame the discussion as: "You need to quit smoking first, and we will help you do that, then we can proceed with evaluation for this procedure."